Plain-English translation of NCT06966674 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial tests tirofiban, a medication that helps prevent blood clots, given as an injection directly into the coronary arteries during emergency heart attack treatment. Some patients will receive the medication while others receive a saline placebo. The goal is to see whether this treatment can prevent or reduce a serious complication called no-reflow, where blood flow doesn't fully return to the heart even after the blocked artery is opened.
Even after doctors successfully open a blocked artery in a heart attack, sometimes blood flow doesn't fully return to the heart tissue—a problem called no-reflow. This medication is being tested to see if it can solve this problem and improve outcomes for heart attack patients.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to either receive tirofiban or saline injected directly into your heart arteries during your emergency heart attack treatment. The injection happens during the same procedure doctors use to open your blocked artery, so it doesn't require extra visits. Researchers will then monitor your recovery and heart function to see whether the medication helped prevent the no-reflow complication.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
Egypt
Sponsor
Kafrelsheikh University
Enrollment target
~60 participants
Started
May 2025
Primary completion
October 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mohammed A Hammad, MD
Kafrelsheikh University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.